Neuroblastoma-derived secretory protein messenger RNA levels correlate with high-risk neuroblastoma

Vasudevan, Sanjeev A.; Russell, Heidi V.; Okcu, M. Fatih; Burlingame, Susan M.; Liu, Zhiyun J.; Yang, Jianhua; Nuchtern, Jed G.

doi:10.1016/j.jpedsurg.2006.09.064

« Previous Next »Journal of Pediatric Surgery
Volume 42, Issue 1 , Pages 148-152, January 2007

Neuroblastoma-derived secretory protein messenger RNA levels correlate with high-risk neuroblastoma

Sanjeev A. Vasudevan
- Division of Pediatric Surgery, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX 77030, USA
Heidi V. Russell
- Department of Pediatrics, Texas Children's Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA
M. Fatih Okcu
- Department of Pediatrics, Texas Children's Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA
Susan M. Burlingame
- Division of Pediatric Surgery, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX 77030, USA
Zhiyun J. Liu
- Division of Pediatric Surgery, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX 77030, USA
Jianhua Yang
- Department of Pediatrics, Texas Children's Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA
- Corresponding authors. Jianhua Yang, Texas Children's Hospital, Feigin Center, Rmc. 0730 08, Mail code- MC3-3320,1102 Bates, Houston, TX 77030, USA. Tel.: +1 832 824 4572; fax: +1 832 825 4732.
Jed G. Nuchtern
- Division of Pediatric Surgery, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX 77030, USA
- Department of Pediatrics, Texas Children's Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA
- Corresponding authors. Jianhua Yang, Texas Children's Hospital, Feigin Center, Rmc. 0730 08, Mail code- MC3-3320,1102 Bates, Houston, TX 77030, USA. Tel.: +1 832 824 4572; fax: +1 832 825 4732.

Abstract

Background/Purpose

In advanced-stage neuroblastoma, bulky disease and systemic dissemination can be controlled with intense surgical and medical therapies; however, recurrence rates are very high in this group indicating that residual disease is rarely eradicated. The need to detect residual disease and predict prognosis is critical to planning appropriate treatment regimens for these patients. Recently, neuroblastoma-derived secretory protein (NDSP) was identified and cloned from neuroblastoma.

Methods

Using quantitative real-time PCR, we tested NDSP messenger RNA (mRNA) expression in 45 neuroblastoma tumor samples and 5 bone marrow samples. Correlation between NDSP expression and age at diagnosis, International Neuroblastoma Staging System, MYCN amplification, and Children's Oncology Group risk stratification was analyzed using Spearman nonparametric correlation.

Results

Neuroblastoma tissue samples show much higher NDSP mRNA levels above control in 43 of 45 samples (96%); moreover, these levels correlate with the Children's Oncology Group neuroblastoma risk group assignment. We also found that bone marrow samples with known tumor infiltration had much higher NDSP mRNA levels than bone marrow from patients without metastasis.

Conclusion

From these data, we conclude that NDSP mRNA levels in neuroblastoma tumor tissue correlate with risk group assignment and may serve as a marker for metastasis in bone marrow.